WCCS/EADO 2016

16th World Congress On Cancers Of The Skin
31 Aug–03 September 2016 | Vienna, Austria

WCCS/EADO 2016

16th World Congress On Cancers Of The Skin
31 Aug–03 September 2016 | Vienna, Austria
Issues with the use of sun screen to protect from skin carcinoma 2:03
Issues with the use of sun screen to protect from skin carcinoma
Herbert Hönigsmann • 31 Aug 2016
Treatment response assessment in melanoma and the challenge of pseudoprogression with immunotherapy 1:30
Treatment response assessment in melanoma and the challenge of pseudoprogression with immunotherapy
Marius Erik Mayerhöfer • 31 Aug 2016
Why dynamic heterogeneity is important for designing drugs in melanoma 1:29
Why dynamic heterogeneity is important for designing drugs in melanoma
Nikolas Haass • 31 Aug 2016
New treatment approaches for Merkel cell carcinoma – checkpoint inhibitors 1:53
New treatment approaches for Merkel cell carcinoma – checkpoint inhibitors
Isaac Brownell • 1 Sep 2016
Sun protection – does it work and how does it work? 2:19
Sun protection – does it work and how does it work?
Herbert Hönigsmann • 1 Sep 2016
Vaccines for melanoma – how to help patients who don’t respond to treatment 3:46
Vaccines for melanoma – how to help patients who don’t respond to treatment
Gerold Schuler • 1 Sep 2016
Psycho-oncology: measuring levels of emotional distress in cancer patients and their families 4:13
Psycho-oncology: measuring levels of emotional distress in cancer patients and their families
Eva Lehner-Baumgartner • 1 Sep 2016
Using mouse models to develop drugs targeting resistance mechanisms in melanoma 1:48
Using mouse models to develop drugs targeting resistance mechanisms in melanoma
Clemens Krepler • 1 Sep 2016
Do fibroblasts have a role in cutaneous carcinogenesis? 2:06
Do fibroblasts have a role in cutaneous carcinogenesis?
Beate Lichtenberger • 1 Sep 2016
The success of the dabrafenib and trametinib combination in BRAF-mutated melanoma 0:59
The success of the dabrafenib and trametinib combination in BRAF-mutated melanoma
Axel Hauschild • 1 Sep 2016
Rare mutation subgroups in melanoma and how to treat them 2:33
Rare mutation subgroups in melanoma and how to treat them
Dirk Schadendorf • 1 Sep 2016
What support can doctors provide patients in terms of pyschological well-being? 2:09
What support can doctors provide patients in terms of pyschological well-being?
Eva Lehner-Baumgartner • 1 Sep 2016
Melanoma patients who discontinued nivolumab and ipilimumab experienced equal or better PFS 3:16
Melanoma patients who discontinued nivolumab and ipilimumab experienced equal or better PFS
Dirk Schadendorf • 1 Sep 2016
Blocking C-MET and BRAF pathways in melanoma to overcome resistance in mouse models 1:30
Blocking C-MET and BRAF pathways in melanoma to overcome resistance in mouse models
Clemens Krepler • 1 Sep 2016
The future of tyrosine kinase inhibitors for melanoma and open questions 2:23
The future of tyrosine kinase inhibitors for melanoma and open questions
Axel Hauschild • 1 Sep 2016
Trial results of vemurafenib, cobimetinib and LDH as a predictive marker in BRAF-mutated melanoma 2:02
Trial results of vemurafenib, cobimetinib and LDH as a predictive marker in BRAF-mutated melanoma
Axel Hauschild • 1 Sep 2016

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals